Palisade Bio CEO Tom Hallam Discusses Gastrointestinal Therapeutics

The CEO of Palisade Bio, Tom Hallam, says that the biopharma company is focused on gastrointestinal therapeutics. One of its drug candidates has shown that it can reduce hospital stays following surgery. PALI was formed from a merger between Leading BioSciences and Seneca Biopharma. The stock began trading on the Nasdaq today.

The Watch List

28 Apr 2021

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US

Palisade Bio CEO Tom Hallam Discusses Gastrointestinal Therapeutics

The CEO of Palisade Bio, Tom Hallam, says that the biopharma company is focused on gastrointestinal therapeutics. One of its drug candidates has shown that it can reduce hospital stays following surgery. PALI was formed from a merger between Leading BioSciences and Seneca Biopharma. The stock began trading on the Nasdaq today.

The Watch List

28 Apr 2021

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US